Bionano_RGB.png
Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
March 19, 2024 08:00 ET | Bionano Genomics
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer...
Logo.png
Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody
December 05, 2023 08:15 ET | Ocean Biomedical, Inc.
Results published in the Journal Immunity share discovery of a new mechanism by which Chi3L1 regulates breast cancer development and progression PROVIDENCE, Rhode Island, Dec. 05, 2023 (GLOBE...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy
March 09, 2023 08:00 ET | Sermonix Pharmaceuticals Inc.
Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic developmentPhase 3 study is supported by previously presented ELAINE-1 and...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
March 06, 2023 09:00 ET | Sermonix Pharmaceuticals Inc.
ST. LOUIS, March 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene
December 19, 2022 09:00 ET | Sermonix Pharmaceuticals Inc.
Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS)One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice
December 08, 2022 12:00 ET | Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Dr Mousumi Majumder_2022 BCC Grant Recipient
Breast Cancer Canada announces $500K in new grant funding
December 01, 2022 13:58 ET | Breast Cancer Canada
SARNIA, Ontario, Dec. 01, 2022 (GLOBE NEWSWIRE) --  Breast Cancer Canada today announced a call for proposals for their 2023 Precision Oncology Research Grants which will award $500,000 in new...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen
September 14, 2022 11:22 ET | Sermonix Pharmaceuticals Inc.
Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene, Sermonix’s...
Dr. Paola Marignani
Breast Cancer Society of Canada Grants $250,000 To Precision Oncology Research at Dalhousie University
June 15, 2022 10:32 ET | The Breast Cancer Society of Canada
SARNIA, Ontario, June 15, 2022 (GLOBE NEWSWIRE) -- The Breast Cancer Society of Canada (BCSC) today announced $250,000 in funding to the Department of Biochemistry and Molecular Biology, Faculty of...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
June 08, 2022 10:00 ET | Sermonix Pharmaceuticals Inc.
Guiding Researchers and Advocates to Scientific Partnerships (GRASP) launched in 2019 to unite patient advocates, physicians and researchers through meaningful discussions of cancer-related...